UCB S.A.
- BID
242.7
- ASK
243
- 159 Units119 Units
- 07/22, 13:20:31 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
40.85%
Market Cap
46.24 Bil.
P/E Ratio
29.12
Dividend Yield
0.43 %
Earnings per Share
8.19 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 242.7 G | 0 Units |
| PRICE DETERMINATION TIME | 07/22/2026 / 01:17:22 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 243.7 | 241.4 |
| PREV. DAY'S PRICE | 242.9 | (07/21) |
| CHANGE DAY BEFORE | -0.20 | -0.08 % |
| 52 WEEK HIGH / LOW | 289.4 (02/19) | 169.85 (07/22) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 1.81 | 5.61 | 8.19 | 10.96 | 13.48 |
DIVIDENDS PER SHARE | 0.95 | 0.97 | 1.02 | 1.48 | 1.51 |
DIVIDEND YIELD IN % | 1.21 % | 0.51 % | 0.43 % | - | - |
DIVIDEND GROWTH IN % | 2.26 % | 2.21 % | 4.32 % | - | - |
PRICE - EARNINGS RATIO | 43.63 | 34.29 | 29.12 | 21.71 | 17.66 |
PRICE - BOOK RATIO | 1.67 | 3.64 | 4.18 | - | - |
PRICE - SALES RATIO | 2.93 | 6.08 | 5.99 | - | - |
PRICE - CASH FLOW RATIO | 24.96 | 34.56 | 21.42 | - | - |
Master Data
| WKN | 852738 |
| ISIN | BE0003739530 |
| SYMBOL | UNC |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | UCB |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 190.36 Mil. |
| MARKET CAPITALISATION | 46.24 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 4.92 % | -2.45 % | -0.57 % | -5.67 % | 40.85 % | 197.23 % | 172.62 % | 3.41 % |
| HIGH | 243.40 | 266.90 | 274.90 | 289.40 | 289.40 | 289.40 | 289.40 | 289.40 |
| LOW | 231.00 | 231.00 | 223.30 | 223.30 | 169.85 | 65.54 | 65.54 | 223.30 |
Dividende
pro Aktie
Company profile
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Structured products for UCB S.A.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.